Lumida
/ATYR
⌘K
aTyr Pharma Inc

aTyr Pharma Inc

ATYR
$0.43USD↓-0.49%-0.00 today

MARKET CAP

42.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$0 – $0

52W RANGE

$0
$7

AI Summary

Stalk
Buy NowMedium

ATYR is forming an early Stage 1 consolidation near multi-year lows with valuations at the lower bound, and mean reversion is permitted. The 9/21 EMAs have flattened and now support price on shallow pullbacks, with no exhaustion signals visible. Price is holding in the lower half of the base, offering a favorable entry around the EMA cluster within the consolidation band. Under a speculative strategy, buying these pullbacks now aligns with upside breakout potential.

  • ↑efzofitimod for pulmonary sarcoidosis addresses key ILD market
  • ↑60% workforce reduction yields $13M annual savings, runway to late 2028
  • ↓Q2 EPS -$0.11 and negative earnings yield underscore profitability woes
Full analysis →

Buying

6

institutions

Selling

2

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
AC

Aqr Capital Management LLC

Q2 2026

BUY2.61 M1.56 M+2.11 M+302.7%0.00%
BI

Blackrock, Inc.

Q2 2026

SELL1.83 M1.09 M+-4.62 M-78.3%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUY1.55 M924.00 K+1.34 M+482.5%0.00%
MM

Millennium Management LLC

Q2 2026

SELL656.05 K391.53 K+-985.20 K-69.4%0.00%
RT

Renaissance Technologies LLC

Q2 2026

BUY165.22 K98.60 K+124.70 K+212.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY150.67 K85.34 K+108.68 K+178.1%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

BUYNEW37.28 K22.25 K+37.28 K+0.0%0.00%
BA

Balyasny Asset Management L.P.

Q2 2026

BUY23.02 K13.73 K+12.69 K+70.5%0.00%